Repurposing an Asthma Reliever
Groundbreaking early research suggests that a widely used asthma medication, montelukast, might offer a new avenue for treating cancers that are notoriously
difficult to manage, such as aggressive forms of triple-negative breast cancer. The study focuses on a protein called cysteinyl leukotriene receptor 1 (CysLTR1), which is present on numerous cell types. Tumors appear to exploit this receptor, effectively turning crucial immune cells called neutrophils into allies that work for the cancer rather than against it. Normally, neutrophils are vital for directly attacking tumor cells, coordinating other immune defenses, and enhancing the efficacy of existing cancer therapies. However, emerging evidence indicates these cells play a significant role in cancer's ability to evade immunotherapy. Under specific circumstances, neutrophils can contribute to an environment that fosters tumor growth and progression. If these findings hold true in further investigations, montelukast, which already targets CysLTR1 and is approved for asthma and allergies, could provide a means to counteract this resistance, potentially making tumors more susceptible to immunotherapy treatments that are currently struggling to be effective against certain cancers.
Immune Cells Hijacked
CysLTR1 is naturally involved in immune responses, aiding in the recruitment of immune cells to infection sites and triggering lung responses like mucus production to expel invaders. However, when this process becomes dysregulated, it can cause problems. In asthma, blocking CysLTR1 offers relief from symptoms like wheezing and shortness of breath. Montelukast performs this function, leading to its approval for asthma and hay fever. The new research, however, points to a more sinister role for CysLTR1 in cancer. Tumor cells appear to manipulate this receptor to induce neutrophils into adopting behaviors that promote tumor development. By releasing specific chemical signals, known as cytokines and cysteinyl leukotrienes, tumors prompt neutrophils to release potent molecules that facilitate the invasion of surrounding healthy tissues by cancer cells. Furthermore, these hijacked neutrophils help shield tumors from attacks by other immune cells that would typically identify and eliminate cancerous cells. This observation is significant as neutrophils are one of the most prevalent immune cell populations, especially in individuals with cancer, and their role in controlling them has been identified.
Promising Preclinical Results
In laboratory experiments using mice, researchers found that inhibiting CysLTR1, either by deactivating the associated gene or administering montelukast, led to a notable slowdown in tumor growth. This intervention also extended the survival times of the mice and improved the responsiveness of tumors that had previously resisted immunotherapy drugs. The positive effects of blocking CysLTR1 were observed across various cancer types in the mouse models, including breast, colon, and melanoma-like cancers. The combination therapy, particularly montelukast with common 'checkpoint blockade' immunotherapies, showed remarkable results, causing tumors that were once unresponsive to shrink significantly under treatment. This is especially relevant for cancers like triple-negative breast cancer, which often do not respond well to checkpoint blockades. The preclinical data suggests that combining montelukast with checkpoint blockades yields impressive outcomes, demonstrated by increased survival rates across multiple cancer types, which is considered a highly encouraging development.
Translating Findings to Humans
Experiments conducted with human cells provided further compelling evidence. When CysLTR1 was blocked in human blood samples, the ability of neutrophils to suppress cancer-fighting immune cells was reduced. Additionally, the maturation of neutrophils into their tumor-promoting, immune-suppressing state was inhibited, indicating that the mechanism observed in mice is also active in humans. Through detailed genetic analysis, the research team elucidated the sequence of events triggered by CysLTR1 that leads to this 'cancer-promoting' mode. They also discovered evidence suggesting this same mechanism has left its mark in extensive cancer patient datasets. Analysis revealed that patients whose tumors exhibited higher levels of this receptor generally experienced poorer outcomes and showed less favorable responses to checkpoint blockade therapies. This suggests that CysLTR1 could potentially serve as a predictive biomarker for immunotherapy resistance and patient prognosis.
Future Directions and Cautions
The research team is hopeful about initiating clinical trials based on these promising results, noting that the availability of montelukast might simplify the process. They also propose that detecting the presence of CysLTR1 in tumors could help doctors identify patients who are likely to resist immunotherapy. While the findings are significant, experts caution that moving quickly into trials does not mean the drug is ready for routine cancer treatment. Thorough evaluation is still required, including determining the optimal dose and schedule, patient selection strategies, safety monitoring, and demonstrating clear benefits when combined with immunotherapy. Furthermore, montelukast has been associated with rare but serious side effects, such as suicidal thoughts, prompting FDA warnings. An alternative approach being considered is targeting the receptor directly with an antibody, which might have fewer side effects than a chemical compound, although this also requires further extensive research. The ultimate goal is to achieve a meaningful clinical impact, though it is currently too early to confirm.
